ScoreComparison
Why is CASI Pharmaceuticals, Inc. ?
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Operating profit has grown by an annual rate -5.94% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -34.69
2
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(Q) At USD 7.22 MM has Fallen at -45.93%
- CASH AND EQV(HY) Lowest at USD 10.32 MM
- DEBTORS TURNOVER RATIO(HY) Lowest at 2.13 times
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -93.80%, its profits have fallen by -47.1%
4
Reducing Promoter Confidence
- Promoters have decreased their stake in the company by -1.18% over the previous quarter and currently hold 9.57% of the company
- Promoters decreasing their stake may signify reduced confidence in the future of the business
5
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -93.80% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is CASI Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
CASI Pharmaceuticals, Inc.
-93.8%
-0.65
147.46%
S&P 500
22.61%
1.71
13.21%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
18.36%
EBIT Growth (5y)
-5.94%
EBIT to Interest (avg)
-34.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
-1.41
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
11.92%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.07
EV to EBIT
-0.37
EV to EBITDA
-0.37
EV to Capital Employed
-1.38
EV to Sales
0.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
NET PROFIT(HY)
Higher at USD -23.9 MM
RAW MATERIAL COST(Y)
Fallen by -116.4% (YoY
INVENTORY TURNOVER RATIO(HY)
Highest at 3.11 times
EPS(Q)
Highest at USD -0.63
-13What is not working for the Company
NET SALES(Q)
At USD 7.22 MM has Fallen at -45.93%
CASH AND EQV(HY)
Lowest at USD 10.32 MM
DEBTORS TURNOVER RATIO(HY)
Lowest at 2.13 times
Here's what is working for CASI Pharmaceuticals, Inc.
Net Profit
Higher at USD -23.9 MM
than preceding 12 month period ended Dec 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
EPS
Highest at USD -0.63
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Inventory Turnover Ratio
Highest at 3.11 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Raw Material Cost
Fallen by -116.4% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for CASI Pharmaceuticals, Inc.
Net Sales
At USD 7.22 MM has Fallen at -45.93%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Cash and Eqv
Lowest at USD 10.32 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debtors Turnover Ratio
Lowest at 2.13 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
